Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.

@article{Cedarbaum2013RationaleFU,
  title={Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.},
  author={Jesse Cedarbaum and Mark J Jaros and Chito Hernandez and Nicola Coley and Sandrine Andrieu and Michael Grundman and Bruno Vellas},
  journal={Alzheimer's & dementia : the journal of the Alzheimer's Association},
  year={2013},
  volume={9 1 Suppl},
  pages={S45-55}
}
BACKGROUND We used the database of the Alzheimer's Disease Neuroimaging Initiative (ADNI) to explore the psychometric properties of the Clinical Dementia Rating Sum of Boxes (CDR-SB) to consider its utility as an outcome measure for clinical trials in early and mild, as well as later, stages of Alzheimer's disease (AD). METHODS We assessed internal consistency, structural validity, convergent validity, and 2-year internal and external responsiveness of the CDR-SB using data from 382 subjects… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
17 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

How well to the ADAScog and its subscales measure cognitive dysfunction in Alzheimer’s disease

  • J Benge, S Balsis, PJ Massman, RS. Doody
  • Dementia Geriatr Cog Disord 2009;28:63–9
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…